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Mesothelial Fibroblast Growth Factor 9 (Fgf9) has been demonstrated by inactivation studies in mouse to be critical for the proliferation of the
mesenchyme. We now show that Fgf9 is also expressed at significant levels in the distal epithelium from the mid-pseudoglandular stages. Using
mesenchymal-free lung endoderm culture, we show that FGF9 triggers the proliferation of the distal epithelium leading to the formation of a cyst-
like structure. On embryonic Fgfr2b−/− lungs, FGF9 induces proliferation of the mesenchyme but fails to trigger a similar effect on the epithelium,
therefore involving the FGFR2b receptor in the proliferative response of the epithelium to FGF9. While FGF9 inhibits the differentiation of the
mesenchyme, the epithelium appears to differentiate normally. At the molecular level, FGF9 up-regulates Fgf10 expression in the mesenchyme
likely via increased expression of Tbx4 and 5 and controls the transcription of Hedgehog targets Ptc and Gli-1 in a Hedgehog-independent manner.
We also show that FGF9 inhibits the activation of the canonical Wnt pathway in the epithelium by increasing Dkk1 expression, a canonical Wnt
antagonist. Our work shows for the first time that FGF9 acts on the epithelium involving FGFR2b to control its proliferation but not its
differentiation and contributes to the regulation of canonical Wnt signaling in the epithelium.
© 2006 Elsevier Inc. All rights reserved.Keywords: FGF9; Mesenchymal and epithelial proliferation and differentiation; Fgfr2b; WNT signaling; Sonic hedgehog signalingIntroduction
Embryonic lung development begins by evagination of the
laryngo-tracheal groove from the foregut endoderm at embry-
onic day 9.5 (E9.5) as two distal buds. Each bud consists of
three different layers: the epithelium, the surrounding mesen-
chyme and the mesothelium. Those two buds subsequently
branch laterally into the surrounding mesenchyme, which is a
source of morphogenetic and differentiation signals for the
branching endoderm.
In the embryonic lung, Fibroblast Growth Factor (FGF)
signaling is an essential component of the regulatory networks
between epithelium, mesenchyme and mesothelium. Fgfr1, 2⁎ Corresponding author. Developmental Biology Program, Saban Research
Institute of Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
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doi:10.1016/j.ydbio.2006.01.020and 3 encode two receptor isoforms (termed IIIb or IIIc) that
are generated by alternative splicing, and each binds a specific
repertoire of FGF ligands (Ornitz et al., 1996). FGFR2-IIIb
(FGFR2b) is found mainly in epithelia and binds four known
ligands (FGF1, FGF3, FGF7 and FGF10), which are primarily
expressed in mesenchymal cells. The importance of FGF
signaling in lung development was first demonstrated by the
complete pulmonary aplasia observed distally to the main stem
bronchi of transgenic mice expressing dominant negative
forms of FGFR-2 (Peters et al., 1994). Furthermore, knockout
mice for Fgfr2 die early during embryogenesis before the
formation of the primary lung buds, whereas those that are null
for the Fgfr2b isoform, but retain Fgfr2c, survive to birth
(Arman et al., 1998; De Moerlooze et al., 2000; Revest et al.,
2001; Xu et al., 1998). Fgfr2b−/− embryos show agenesis
and dysgenesis of multiple organs, including the lungs,
indicating that signaling through this receptor is critical for
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esis. During postnatal life, FGFR3 and -4 play a critical role in
controlling the formation of the secondary septae, as indicated
by the failure in alveolarization of Fgfr3/Fgfr4 double null
mutant pups (Weinstein et al., 1998).
FGF10 is the main mesenchymal FGF ligand acting on the
lung epithelium during the early pseudoglandular stage. FGF10
is part of the 22 members of the FGF family (Ornitz and Itoh,
2001). In the developing lung, Fgf10 is expressed in the distal
mesenchyme at sites where prospective epithelial buds will
appear (Bellusci et al., 1997b). FGF10 has been shown to
interact with FGFR1b and FGFR2b in vitro (Ornitz et al., 1996).
Mice deficient for Fgf10 show multiple organ defects including
lung agenesis (Ohuchi et al., 2000; Sekine et al., 1999). The
similarity of phenotype exhibited by these knockout embryos
compared to the Fgfr2b null embryos supports the idea that
FGF10 is the main ligand for FGFR2b during the early
embryonic phase of development (De Moerlooze et al., 2000).
Thus, the paradigm proposed so far is that FGF10 expressed by
the mesenchyme acts on the epithelium principally via FGFR2b
and secondarily via FGFR1b.
FGF9 is another important player in lung development.
Colvin et al. showed that, at E10.5, Fgf9 is expressed in the
epithelium of the developing bronchi and in the mesothe-
lium (Colvin et al., 1999). However, at E12.5, Fgf9 was
expressed in the mesothelium and no longer detected in the
endoderm. To date, FGF9 is the only FGF expressed in the
mesothelium. Classical inactivation of Fgf9 leads to a
reduction in proliferation of the lung mesenchyme resulting
in severely reduced branching of the lung epithelium
(Colvin et al., 2001). Mesothelial FGF9 is thought to act
on the underlying mesenchyme via FGFR2c (Ornitz et al.,
1996). FGF9 has also been demonstrated to inhibit the
differentiation response of the mesenchyme to SHH without
altering proliferation (Weaver et al., 2003). Therefore, FGF9
has a great potential for being a key molecule that maintains
lung mesenchymal progenitor cells in an undifferentiated
state. This pool of undifferentiated cells is indeed to give
rise to a different mesenchymal cell types during the
pseudoglandular and subsequent stages. However, the
reported early expression pattern of Fgf9 showed also low
expression in the lung epithelium. In support of this
observation, we confirmed that Fgf9 was expressed in the
mesothelium and at low levels in the distal epithelium up to
E12.5. At E13.5, Fgf9 expression in the epithelium increases
and, at E14.5, Fgf9 is no longer detected at significant
levels in the mesothelium but is expressed in the distal
epithelium. These observations lead to examine the role of
FGF9 in the lung epithelium. We have taken advantage of
the availability of recombinant FGF9 protein as well as of
different transgenic and knockout mice to further evaluate
the role of FGF9 on the epithelium and mesenchyme during
early lung development. Our results show that FGF9 acts
differentially on the epithelium and on the mesenchyme.
Therefore, FGF9 appears to be a major player in epithelial/
mesenchymal and mesothelial/mesenchymal interactions dur-
ing lung development.Materials and methods
Mice
C57BL/6 wild-type and Flk-1nLac−Z/+ mice were generated by Dr. Rossant
and obtained from Jackson laboratories. Fgf10+/− and Fgfr2b+/− mice were
kindly provided by Dr. Itoh and Dr. Dickson, respectively (De Moerlooze et al.,
2000; Sekine et al., 1999). Mlc1v24 mice containing an Fgf10 enhancer-trap
nlacZ transgene (these mice are also called Fgf10LacZ for simplification
(Mailleux et al., 2005) and are a gift from Dr. Kelly (Kelly et al., 2001).
TOPGAL mice expressing the β-galactosidase gene under the control of a LEF/
TCF and β-catenin inducible promoter were a gift from Dr. Fuchs (DasGupta
and Fuchs, 1999).
Mutant embryos
Fgf10−/− (n = 6) and Fgfr2b−/− (n = 6) were generated as previously
described (De Moerlooze et al., 2000; Sekine et al., 1999) on the C57Bl/6
background. Wild-type (Wt) or heterozygote littermates were used as controls.
Whole lung culture
Timed-pregnant C57BL/6 wild-type or transgenic mice were sacrificed on
postcoitum day 12.5 (E12.5), and the embryos were harvested. Lung primordia
(n = 8 for each condition) were isolated from embryos by microdissection under
sterile conditions. Embryonic lungs were placed on 8.0-μm Nuclepore Track-
Etch membrane (Whatman) and cultured in DMEM:F12 medium (Gibco, Grand
Island, NY) supplemented with 50 units/ml penicillin/streptomycin and 0.5%
fetal bovine serum (FBS). About 1 ml of medium was added to each dish to
establish an air fluid interface at the level of the explants. The cultures were
maintained in 100% humidity with an atmosphere of 95% air and 5% CO2 for 2
days. The medium was changed every day.
Exogenous FGF9 treatment
Exogenous recombinant human FGF9 (R&D, Minneapolis, MN) was added
to cultured E12.5 lung explants. A dose response analysis was done using 40,
80, 150, 200 and 250 ng/ml FGF9 in culture media. The optimal dose to induce a
clear biological effect on whole lungs was 200 ng/ml. No significant difference
between 200 and 250 ng/ml was noticed. Therefore, an FGF9 concentration of
200 ng/ml was maintained during the whole culture by replacing the media
every 24 h.
In vitro assay of isolated lung epithelium and mesenchyme
E13.5 mouse lung was isolated and treated with undiluted dispase (BD
Biosciences, San Jose, CA) for 30 min at 4°C. The distal mesenchyme was
separated from the distal epithelium using fine tungsten needles and transferred
separately into Matrigel™ (BD Biosciences, San Jose, CA) diluted 1:1 with
culture medium (DMEM:F12/5% FBS/penicillin–streptomycin + glutamine) in
a four-well Nunc plate. Polymerization of the Matrigel™ was triggered at 37°C
for 30 min. After polymerization, 500 μl of culture medium containing 200 ng/
ml of FGF9 was gently added to the Matrigel™ layer. The explants were grown
for 48 h at 37°C in a 5% CO2 incubator.
Detection of β-galactosidase activity
Cultured lungs in the absence or presence of FGF9 (n = 6 for each condition)
from heterozygous Flk-1nLac−Z/+, Fgf10LacZ/+ and TOPGAL+/+mice were briefly
fixed 2 min in 4% paraformaldehyde (in phosphate-buffered saline—PBS) and
incubated with X-gal as previously described (De Langhe et al., 2005).
Proliferation assay
The lung explants were incubated with bromodeoxyuridine (BrdU)
(Amersham Biosciences UK Limited; diluted 1:500) for the last 3 h of the
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processed for paraffin sectioning at 5 μm. The sections were then treated
with monoclonal anti-bromodeoxyuridine (Clone BU-1) RPN 202 as
recommended by the manufacturer (Amersham Biosciences). Cy3-labeled
anti-mouse secondary antibody was used. The slides were mounted using
Vectashield® containing DAPI medium. The sections were then photo-
graphed. Lung tissue, distal to the trachea, forms in both mutants. A line
perpendicular to the cleft separating the two primary bronchi is drawn. The
epithelial layer below this line is considered as distal (lung) epithelium. The
epithelial layer above this line is considered as proximal (tracheal)
epithelium. Distal (lung) epithelial and mesenchymal cells of Fgf10−/−
lungs (n = 2), FGF9-treated Fgf10−/− lung (n = 2), Fgfr2b−/− lungs (n = 2)
and FGF9-treated Fgfr2b−/− lungs (n = 2) were counted and scored as
labeled or unlabeled. The normalization was done as the percent of all cells
in each individual layer. The total number of distal epithelial and
mesenchymal cells counted respectively for each condition was as follows:
Fgf10−/− lungs (489; 175), FGF9-treated Fgf10−/− lung (610; 294), Fgfr2b−/−
lungs (310; 762) and FGF9-treated Fgfr2b−/− lungs (532; 319). The data
were analyzed by Student's t test. Results were determined to be significant
if P b 0.05 (*).
Antibodies and immunofluorescence
Via standard protocol, slides were treated with different antibodies. Cy3-
conjugated mouse monoclonal anti-smooth muscle actin clone 1A4 (Sigma) was
used at a dilution of 1:200. Rabbit anti-pro-SP-C was kindly provided by Dr. J.
Whitsett (Children's Hospital Medical Center, Cincinnati, Ohio) and was used at
a dilution of 1:1000. Cy3-conjugated goat anti-mouse and FITC-conjugated goat
anti-rabbit (Jackson Immunoresearch Laboratories) diluted 1:200 were used as
secondary antibodies (all samples were mounted with Dapi-labeled Vecta-
shield® and photomicrographs were taken).
Whole-mount and section in situ hybridization
Microdissected and cultured lungs were fixed in 4% paraformaldehyde
for 20 min and dehydrated in ethanol. The whole-mount in situ hybridization
protocol used was based on a previously described method (Winnier et al.,
1995). For in situ hybridization on section, lungs were processed for paraffin
sectioning and treated as described (Bellusci et al., 1996). The following
mouse cDNAs were used as templates for the synthesis of digoxigenin-
labeled riboprobes: a 528 bp fragment of Fgf9 (provided by Dr. Ornitz), a
642 bp fragment of Shh (Bellusci et al., 1997a), a 622 bp fragment of Fgf7
clone (provided by Dr. Ivor Mason, UK), an 841 bp fragment of Ptc
(Bellusci et al., 1996) and a 1.7 kb partial cDNA of Gli-1 (Grindley et al.,
1997), an 818 bp full-length Dkk1 probe (provided by Dr. Christopher
Niehrs), a 1.3 kb Tbx4 probe and a 1.1 kb Tbx5 probe (provided by
Dr. Papaioannou).
Preparation of mesenchymal cell cultures and FGF treatment
Whole lungs were dissected at E14.5 and subjected to trypsin digestion to
give rise to single cells. Mesenchymal cells were separated from epithelial cells
by differential adhesion as described previously (Lebeche et al., 1999). Fifty
minutes after plating, 200 ng/ml of FGF9 was added to the mesenchymal cells.
The cells were cultured in DMEM/F12 medium containing penicillin/
streptomycin and 0.5% heat-inactivated FBS in the presence or absence of
FGF9. After 48 h of culture, total RNA was extracted and processed for
evaluation of gene expression by semi-quantitative RT-PCR.
Semi-quantitative RT-PCR
Total RNA was extracted from a pool of 4 lungs (cultured with or without
FGF9 for 48 h) or from primary cultures of lung mesenchyme using the RNeasy
Total RNA kit (Qiagen). Three independent experiments were conducted. The
RNAwas reverse-transcribed using hexamers with TaqMan Transcript Reagent
kit (Applied Biosystem) according to the manufacturer's conditions. 1/50 of the
cDNA prepared from 1 μg RNA was subjected to PCR using murine gene-specific primers for Fgf10 (5′-TGT TTT TTG TCC TCT CCT GGG AG-3′ and
5′-GGA TAC TGA CAC ATT GTG CCT CAG-3′), Fgf7 (5′-TCT GCT CTA
CAG ATC ATG C-3′ and 5′-TAG GTTATT GCC ATA GGA AG-3′), Shh (5′-
CCC TTTAGC CTA CAAGCA G-3′ and 5′-GAG GAA GTC GCT GTA CAG
C-3′), Ptc (5′-GAA GGC GCTAAT GTT CTG AC-3′ and 5′-TAC CTA GGA
GGT ATG CTG TC-3′), Gli-1 (5′-TGC CAG ATATGC TTC AGC CA-3′ and
5′-TGT GGC GAA TAG ACA GAG GT-3′), Dkk1 (5′-CCA GAC TCT TGA
CAA CTA CC-3′ and 5′-GTT TAC AGA TCT TGG ACC AG-3′), Tbx4 (5′-
TCA CTG GAT GCG GCA GTT GGT CTC T-3′ and 5′-CAG GTG GGT GCA
AAA GGC TGT GTT T-3′), Tbx5 (5′-CCA CTG GAT GCG ACA ACT TGT
CTC C-3′ and 5′-GAC GTG GGT TGC AAA ACG CAG TGT TC-3′),
Cytokeratin 18 (5′-CTTGCTGGAGGATGGAGAAG-3′ and 5′-CTGCA-
CAGTTTGCATGGAGT-3′), β-actin (5′-GTG GGC CGC TCT AGG CAC
CAA-3′ and 5′-CGG TTG GCC TTA GGG TTC AGG G-3′). β-actin was used
as internal control and as a reference for quantification. No amplicons were
detected with negative controls, water and minus RT controls. For semi-
quantitative PCR, target sequences were amplified within the linear amplifica-
tion range between 25 and 34 cycles at 55°C (for Fgf7, Fgf10, Dkk1), 58°C (for
Shh, Tbx4, and Tbx5) or 60°C (for Ptc, Gli-1, and Cytokeratin 18) in order to
yield visible products. PCR products were separated by electrophoresis on a 1%
agarose gel and stained with ethidium bromide. Photographs were taken with a
Vilbert–Loumart apparatus, and the intensity of the bands was determined by
densitometry with NIH Image software (http://rsb.info.nih.gov/nih-image/)
using Gel Plotting Macros (http://www.chemie.uni-marburg.de/∼becker/image.
html).
Western blot analysis
Cultured lung primary mesenchymal cells were disrupted immediately in
SDS buffer containing protease inhibitors and sodium fluoride. Equal amounts
of total lung protein from each assayed sample were used for chemilumines-
cent Western analysis (Roche Molecular Biochemicals) on Immuno-Blot
PVDF membrane (Bio-Rad, Hercules, CA). Immunoblotting was performed
using antibodies against GLI-3 (H-258, Santa Cruz Biotechnology, Santa
Cruz, CA) and mouse anti-actin (ICN Biomedicals, Aurora, OH) at
recommended dilutions (1:1000 for the GLI-3 antibody and 1:10,000 for
the actin antibody).Results
Fgf9 is first expressed in the mesothelium and later on in the
distal lung epithelium
Whole-mount in situ hybridization (WMISH) with Fgf9
antisense digoxigenin-labeled probe followed by vibratome
sectioning was used to detect Fgf9 expression in the embryonic
lung between E12.5 and E14.5. As previously described by
Colvin et al. (2001), Fgf9 expression is detected at high levels in
the mesothelium of E12.5 lungs (Figs. 1A–C). However, at
E13.5, we find that Fgf9 expression is detected in the
mesothelium as well as the distal epithelium (Figs. 1D–F). At
E14.5, Fgf9 is no longer detected at significant levels in the
mesothelium but is restricted to the distal epithelium (Figs. 1G–
I). To exclude potential edge artifacts, we have also carried out
WMISH with the Fgf9 sense control probe as well as in situ
hybridization on sections with Fgf10, Hnf3β and Fgf9 antisense
probes on E14.5 lungs. While Fgf9 sense control probe does not
show any signal above background (Fig. 1J), Fgf10 and Hnf3β
are exclusively expressed in the distal mesenchyme (Fig. 1K)
and epithelium (Fig. 1L), respectively. Confirming our previous
result, Fgf9 is expressed in the distal but not the proximal
epithelium (Fig. 1M).
Fig. 1. FGF9 is first expressed in the mesothelium and later on in the distal
epithelium. (A, B) Whole-mount in situ hybridization using Fgf9 digoxigenin-
labeled antisense probe on E12.5 lungs showing high levels of expression in the
mesothelium. (C) Vibratome section of the lung shown in panel A. (D–F) At
E13.5,Fgf9 is nowdetected in themesothelium aswell as in the epithelium. (G–I)
At E14.5, Fgf9 is mainly detected in the distal epithelium. (J) No specific signal
above background is detected using Fgf9 sense probe on E14.5 lungs. (K) In situ
hybridization on E14.5 lung sections using Fgf10 antisense probe showing high
levels of expression in the mesenchyme. (L) Hnf3-β antisense probe reveals a
specific expression throughout the epithelium. (M) Fgf9 antisense probe reveals
an expression in the distal epithelium (arrows) but is absent from the bronchial
epithelium (Br).
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on in vitro culture of mouse embryonic lungs
In vitro cultures of whole lungs isolated at embryonic days
12.5 (E12.5) were carried out over a period of 48 h to test the
biological effect of FGF9 on lung branching (Fig. 2). Without
the addition of FGF9, the lungs show an increasing number of
distal end buds (+206% ± 3%, P b 0.001 between 0 and 48 h;
Figs. 2A–C, G). By contrast, in the presence of 200 ng/ml of
FGF9 (the same concentration was used throughout this study),
a notable expansion of the mesenchyme is observed after 24 h of
culture (Fig. 2E) associated with a dilation of the distal
epithelium. The effect on the dilation of the epithelium is evenmore pronounced after 48 h of culture (Fig. 2F). Morphometric
analysis shows only a modest increase in the number of distal
end buds after 48 h (+6% ± 0.2%, P b 0.001 between 0 and 48 h,
Fig. 2G). Hematoxylin–eosin staining of the lungs after 24 h
shows the expansion of the mesenchyme over several cell layers
(compare Figs. 2I and J). After 48 h of exposure to FGF9, the
epithelium shows a decrease in the apical to basal distance
(compare Figs. 2K and L). The perimeter of the distal buds at
0 h and 48 h was compared between control and FGF9-treated
lungs (Fig. 2H). While a 47% ± 6.4% (P b 0.001) increase was
noted in the control, FGF9-treated lungs show a significant
dilation (125% ± 4%, P b 0.001).
These results suggest that FGF9 could act both on the
mesenchyme and on the epithelium. To test this possibility, the
distal epithelium and mesenchyme of E12.5 lungs were
separated and individually cultured in Matrigel in the presence
or absence of FGF9 (Fig. 3). Isolated mesenchymal explants
cultured for 48 h in control media condense and die (Figs. 3A,
B). In the presence of FGF9, a considerable increase in the size
of the mesenchymal explant is observed associated with many
elongated mesenchymal cells invading the Matrigel at the
periphery (Figs. 3C, D). As previously described, after 48 h of
culture, isolated epithelial explants die (Bellusci et al., 1997b).
By contrast, in the presence of FGF9, the epithelium grows to
form a cyst-like structure (Fig. 3H).
In conclusion, FGF9 is able to act directly on the
mesenchyme and on the epithelium. This result indicates that
a receptor for FGF9 must be present at the surface of the distal
epithelium. Since the biological activity observed with FGF9 is
very similar to the one reported with FGF7 (Bellusci et al.,
1997b) and FGF7 has been shown to act only through FGFR2b,
we decided to evaluate the role of FGFR2b in the response of
the epithelium to FGF9.
Fgfr2b expression is needed for the activity of FGF9 on the
epithelium
In vitro culture using lungs isolated from Fgfr2b and Fgf10
null embryos was carried out. Contrarily to what was previously
reported by De Moerlooze et al. (2000), E11.5 Fgfr2b null lungs
show formation of the first two bronchi (hereafter described as
lung epithelium; Fig. 4A). A similar phenotype is observed in
Fgf10 null lungs at the same stage (Fig. 4B). By contrast, at
E13.5, a significant phenotypical difference is observed
between Fgf10 and Fgfr2b null lungs. Fgfr2b−/− lungs show
moderate growth of the right bronchus and maintenance of the
left bronchus with a visible cleft separating the 2 bronchi (Fig.
4C), while Fgf10−/− lungs show only the right bronchus with no
evident sign of a cleft (Fig. 4D). These results show that lung
epithelium forms in both mutants and that FGF10 does not only
signal through FGFR2b during lung development. Interestingly,
expression of Surfactant protein c (Spc) and Bone morphoge-
netic protein 4 (Bmp4), two FGF10 downstream targets in the
lung, was not detected in the distal epithelium of both mutants
(data not shown), suggesting that these two distal epithelial
markers are downstream of the FGF10/FGFR2b signaling.
E12.5 Fgfr2b−/− lungs were cultured on filters in the absence or
Fig. 3. Effect of FGF9 on isolated distal lung epithelium and mesenchyme. (A, B) Isolated distal mesenchyme grown for 48 h in the absence of FGF9 undergoes
necrosis (B). (C, D) In the presence of FGF9, the mesenchymal explant grows and many mesenchymal cells invading the Matrigel are observed in periphery. (E, F)
Isolated distal epithelium grown for 48 h in the absence of FGF9 undergoes necrosis (F). (G, H) In the presence of FGF9, the epithelial explant grows considerably to
form a cyst-like structure. Scale bar: A–H 80 μm.
Fig. 2. FGF9 induces expansion of the mesenchyme and the dilation of the epithelium in lung grown in vitro. (A–C) E12.5 lung is grown for 48 h in the absence of
FGF9. Note the increase in branching. (D–F) E12.5 lungs grown for 48 h in the presence of FGF9. Note the dilation of the epithelium and mesenchyme as early as after
24 h of culture (E). After 48 h (F), the effect on the epithelium is even more pronounced. (G) Quantification of the number of terminal branches in lung grown in the
absence or presence of FGF9. Note that, in the presence of FGF9, there is a clear decrease in the branching of the epithelium. (H) Quantification of the dilation of the
distal bud by measuring the perimeters of the distal bud at 0 and 48 h and calculating the ratio (perimeter at 48 h/perimeter at 0 h). Note the significant increase in
dilation of the distal end buds in the presence of FGF9. (I, J) Hematoxylin–eosin staining of paraffin section of the lungs shown in panels B and E. Note the clear
expansion of the mesenchyme upon treatment by FGF9. (I′–J′) High magnification of the distal epithelium of the lungs shown in I and J indicating that the height of
the epithelium is also decreased (double arrows in panels I′ and J′). (K, L) Hematoxylin–eosin staining of paraffin section of the lungs shown in panels C and F. The
increase in the proportion of distal mesenchyme is less pronounced at that stage. (K′, L′) High magnification of the distal epithelium of the lungs shown in panels K and
L indicating that the height of the epithelium is decreased. Scale bar: A–F 400 μm; I–L 30 μm; I′–L′ 10 μm.
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the epithelium distal to the trachea still occurs after 48 h of
culture (compare Figs. 4E and F). Analysis of BrdU
incorporation in the lung epithelium shows a clear proliferationof the epithelium and mesenchyme (Fig. 4G). As already shown
in wild-type lungs (Fig. 2E), FGF9 triggers the expansion of the
mesenchyme in Fgfr2b−/− lungs (Fig. 4I). However, FGF9
failed to induce the dilation of the distal epithelium (Fig. 4I).
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epithelial proliferation upon addition of FGF9 (9.8% ± 0.7% vs.
36.3% ± 2.0%, P = 0.008, in treated vs. non-treated respectively,
Figs. 4G, J and K). As expected, FGF9 triggers an increase in
distal mesenchymal proliferation in Fgfr2b−/− lungs
(70.5% ± 9.5% vs. 18.2% ± 3.6%, P = 0.001 in treated versus
non-treated respectively, Figs. 4G, J and K). Since Fgf10−/−
lungs exhibit a similar phenotype than Fgfr2b−/− lungs (Figs.
4A, B), we investigated whether Fgfr2b expression in the
epithelium of Fgf10 mutant lungs would enable the respon-
siveness of the mutant epithelium to FGF9. Upon addition of
FGF9, branching of the distal epithelium and mesenchymal
expansion is observed (Fig. 4P). In addition, increased
proliferation is observed in the mesenchyme (44.7% ± 6.2%
vs. 18.0% ± 1.8%, P = 0.016, in treated vs. non-treated
respectively) and in the epithelium (26.8% ± 6.8% vs.
8.2% ± 0.2%, P = 0.042, in treated vs. non-treated respectively)
(Figs. 4N, Q and R). In conclusion, our results demonstrate that
the activity of FGF9 on the epithelium requires Fgfr2b
expression.
FGF9 triggers a decrease in mesenchymal differentiation but
does not affect the differentiation of the distal epithelium
FGF9 has been reported to affect lung mesenchymal survival
(Colvin et al., 2001), and our results show that it also controls
mesenchymal proliferation (Figs. 2 and 3). However, the role of
FGF9 in the differentiation of the different mesenchymal cell
types is still unclear. We analyzed initially smooth muscle cells
formation. Smooth muscle actin (SMA) is a terminal differen-
tiation marker for smooth muscle cells. Fig. 5A shows the
expression of SMA, in wild-type whole lung explants after 48 h
of culture. SMA expression is mostly found in the layer of
mesenchyme directly adjacent to the epithelium of the primary
and secondary bronchi. In the presence of FGF9, the expression
of SMA is significantly reduced (Figs. 5A, B). In order to
evaluate the role of FGF9 in the differentiation of the SMC, we
carried out primary cultures of E14.5 lung mesenchymal cells.
In the absence of FGF9, expression of SMAwas detected in all
the cells after 24 h in culture (Fig. 5C) as previously described
(Yang et al., 1998). In the presence of FGF9, SMA expression
was no longer detected (Fig. 5D), demonstrating that FGF9 is
able to prevent the default differentiation of the primary
mesenchymal cells into smooth muscle cells. To determine if
FGF9 could selectively induce the proliferation of subsets of
mesenchymal cells, we carried out lung primary mesenchymalFig. 4. Effect of FGF9 on Fgfr2b−/− and Fgf10−/− lungs. (A) E11.5 Fgfr2b−/− and (B)
presence of a bifurcation. (C) E13.5 Fgfr2b−/− lung still has 2 distal buds (arrows), w
lung grown in vitro in the absence of FGF9 for 48 h displays a significant expansion o
incorporation shows proliferation in the epithelium and mesenchyme. (H, I) E12.5 Fg
expansion of the mesenchyme. (J) After 48 h of culture, BrdU incorporation show
mesenchyme. (K) Quantification of proliferation in epithelium and mesenchyme in F
FGF9 for 48 h displays a moderate expansion of the epithelium and mesenchyme. (N
epithelium and mesenchyme. (O, P) E12.5 Fgf10−/− lung grown in vitro in the presenc
as well as an expansion of the mesenchyme. (Q) After 48 h of culture, BrdU incorpora
to the control. (R) Quantification of proliferation in epithelium and mesenchyme in F
bar: E, F, H, I, L, M, O, P 220 μm; G, J, N, Q 160 μm.cells cultures from Fgf10LacZ lungs (Mailleux et al., 2005).
After 24 h in culture, FGF9 was not able to induce differential
proliferation of LacZ-positive cells, here as a read out for Fgf10-
expressing cells (Figs. 5E, F; 28% ± 3.18% vs. 22.8% ± 2.35
P b 0.01, in the absence or presence of FGF9, respectively). We
also investigated the status of the vascular system by using the
Flk1nLacZ transgenic mice (Shalaby et al., 1995). X-gal staining
illustrates that, in FGF9-treated explants (Fig. 5H), blood vessel
formation is impaired compared to untreated lungs (Fig. 5G).
Quantification of the surface corresponding to the β-galacto-
sidase staining, reported as a percentage of the total lung
surface, shows a significant reduction upon FGF9 treatment
(21.4% ± 0.5% vs. 7.5% ± 0.1% respectively, P ≤ 0.001). By
contrast, expression of Surfactant protein C, a marker for type II
epithelial cells, is not affected upon FGF9 treatment (compare
Figs. 5J and I). In conclusion, FGF9 affects mesenchymal
differentiation but not epithelial differentiation.
FGF9 regulates Fgf10 expression likely via up-regulation of
Tbx4 and Tbx5
We chose whole-mount in situ hybridization rather than RT-
PCR for this analysis to avoid any complications arising from
differences in the ratio of epithelium vs. mesenchyme in the
FGF9-treated lungs. The expression pattern of Fgf10 has been
examined using a Fgf10LacZ reporter mouse (Kelly et al., 2001;
Mailleux et al., 2005). High levels of β-galactosidase
expression are observed in E12.5 Fgf10LacZ/+ lungs after 48 h
of culture in control media (Figs. 6A, C). The expression is
located in the most distal mesenchyme as previously described
(Bellusci et al., 1997b; Mailleux et al., 2005). By contrast, the
lungs exposed to FGF9 show an expansion of the mesenchyme
expressing Fgf10 (Figs. 6B, D). This Fgf10 expression domain
does not enter in contact with the distal epithelium (data not
shown). In the developing limbs, Fgf8 expressed by the apical
ectodermal ridge signals to the mesenchyme to maintain/induce
the expression of Tbx4 and 5 genes, which in turn up-regulate
Fgf10 (Agarwal et al., 2003; Sekine et al., 1999; Takeuchi et al.,
2003; Xu et al., 1998). TBX4 and 5 play a similar role in the
lung (Cebra-Thomas et al., 2003; Sakiyama et al., 2003).
Therefore, FGF9 is a candidate molecule activating the
expression of these transcription factors. Tbx4 (Figs. 6E–H)
and Tbx5 (data not shown) were up-regulated in the
mesenchyme of FGF9-treated lungs (Figs. 6F, H) suggesting
their involvement in the observed Fgf10 up-regulation. In order
to confirm the qualitative results obtained by whole-mount inFgf10−/− lungs showing the formation of distal lung (arrows) associated with the
hereas (D) E13.5 Fgf10−/− lung only has one distal bud. (E, F) E12.5 Fgfr2b−/−
f the epithelium (black arrows) and mesenchyme. (G) After 48 h of culture, BrdU
fr2b−/− lung grown in vitro in the presence of FGF9 for 48 h only displays a clear
s decreased proliferation in the epithelium but increased proliferation in the
gfr2b−/− distal lung. (L, M) E12.5 Fgf10−/− lung grown in vitro in the absence of
) After 48 h of culture, BrdU incorporation shows moderate proliferation in the
e of FGF9 for 48 h displays a significant budding of the epithelium (black arrow)
tion shows increased proliferation in the epithelium and mesenchyme compared
gf10−/− distal lung. e: epithelium; m: mesenchyme; tr: trachea; Th, thymus. Scale
Fig. 5. Effect of FGF9 on mesenchymal and epithelial differentiation. (A, B)
Analysis of the differentiation of the parabronchial smooth muscle cells using
smooth muscle actin (SMA) as a terminal differentiation marker. SMA
expression by immunofluorescence after 48 h of culture in the absence (A) or
presence (B) of FGF9. SMA is detected around the bronchial epithelium. Note
the drastic decrease in SMA expression upon treatment with FGF9. (C, D) SMA
expression by immunofluorescence on lung primary mesenchymal cells after
48 h of culture in the absence (C) or presence (D) of FGF9. (E, F) Determination
the proportion of LacZ-positive cells (reflecting the proportion of Fgf10-
expressing cells) after X-gal staining in lungmesenchymal primary cultures from
Fgf10LacZ lungs in FGF9-treated (F) and non-treated control cells (E). (G, H)
Analysis of endothelial cell differentiation using Flk1nLacZ/+ lungs grown in the
absence or presence of FGF9 for 48 h. Note the clear reduction ofβ-galactosidase
expression upon treatment with FGF9 (H). (I, J) Detection of Surfactant protein c,
a marker of type II epithelial cells, by immunofluorescence. Note that there is no
significant change in SP-C expression upon FGF9 treatment (J).
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primary cultures of lung mesenchymal cells isolated from E13.5
wild-type lungs. We observed an increase in the expression of
Fgf10 (+99%), Tbx4 (+91%) (Fig. 6I) and Tbx5 (data notshown). Since FGF9 does not amplify Fgf10-positive cells
(Figs. 5E, F), the FGF9-induced increase in the expression of
Fgf10, Tbx4 and Tbx5 is likely on a per cell basis. Given the
striking effect of FGF9 on the distal epithelium, we aimed to
determine the involvement of additional signaling pathways
known to trigger epithelial dilation.
FGF9 inhibits the canonical Wnt signaling in the distal
epithelium
We have previously shown that inhibition of canonical Wnt
signaling results in epithelial dilation (De Langhe et al., 2005).
Canonical Wnt signaling also regulates lung branching
(Mucenski et al., 2003; Okubo and Hogan, 2004). We used
TOPGAL mice (DasGupta and Fuchs, 1999) to monitor the
status of canonical Wnt signaling in the lung grown in the
presence or absence of FGF9. In the control lung, we observe
strong but uneven levels of β-galactosidase activity in the distal
epithelium (Figs. 7A, C). This variation in the expression level
of β-galactosidase reflects the progressive decline in canonical
Wnt signaling observed from E13.5 onwards (De Langhe et al.,
2005). In the presence of FGF9, an accelerated decrease in
TOPGAL expression is observed (Figs. 7B, D). These results,
based on the detection of the activity of the β-galactosidase
protein, which is very stable, are likely underestimating the
decrease in LacZ mRNA expression upon FGF9 treatment. The
inserts in Figs. 7A and B show indeed a significant decrease in
LacZ expression at the mRNA levels in FGF9-treated lung. We
have previously described that Dickkopf-1 (DKK1), a soluble
inhibitor of canonical Wnt signaling, is expressed in the distal
lung epithelium from E13.5 (De Langhe et al., 2005). We show
that FGF9 treatment up-regulates Dkk1 expression in the distal
lung epithelium (Figs. 7F, H). Dkk1 up-regulation (+283%) by
FGF9 was also confirmed by semi-quantitative RT-PCR on
whole lung explants cultured for 48 h (Fig. 7I).
FGF9 triggers the up-regulation of SHH downstream target
genes Ptc and Gli-1 in the mesenchyme
The dilation of the epithelium observed with FGF9 is
similar to the one observed with FGF7 (Bellusci et al.,
1997b). We therefore considered the expression of Fgf7 as
well as upstream regulators of Fgf7: the members of the Sonic
hedgehog signaling pathway (Lebeche et al., 1999). No
significant differences in the expression levels were observed
for Fgf7 (data not shown) and Shh by whole-mount in situ
hybridization (Figs. 8A–D). However, the expression of Ptc
and Gli-1, two transcriptional targets of the Sonic Hedgehog
pathway, is up-regulated in the lung treated with FGF9
(compare Figs. 8E and F, I and J, respectively). In order to
confirm our results, primary cultures of E14.5 lung mesen-
chymal cells were treated with FGF9 and gene up-regulation
was confirmed using semi-quantitative RT-PCR. Up-regula-
tion of Ptc (+162%), Gli-1 (+88%) as well as Fgf7 (+287%)
is observed upon treatment with FGF9, while Dkk1 (Fig. 8M)
and cytokeratin 18 (data not shown) expressed only by the
epithelium (De Langhe et al., 2005; Thorey et al., 1993;
Fig. 6. Effect of FGF9 treatment on the expression of Fgf10 and Tbx4. (A, B) β-galactosidase expression in E12.5 Fgf10LacZ/+ lungs grown in vitro in the absence of FGF9 for 24 h is used to follow Fgf10 expression (A).
Note β-galactosidase expression in the distal mesenchyme. In the presence of FGF9 (B), there is a clear increase in β-galactosidase expression distally. (C, D) High magnification of the lungs shown in A and B. Note that
the increase in β-galactosidase expression upon treatment with FGF9 correlates with the expansion of the distal mesenchyme. (E, F) Whole-mount in situ hybridization for Tbx4 in control and FGF9-treated lungs after
48 h of culture shows a significant change in Tbx4 expression. (G, H) High magnification of the lungs shown in E and F. Note that the increase in Tbx4 expression upon treatment with FGF9 takes place in the
mesenchyme. (I) Semi-quantitative RT-PCR has been used to investigate changes in gene expression in primary culture of lung mesenchyme upon treatment with FGF9. A significant increase in Fgf10 and Tbx4
expression is observed. β-actin is used as a housekeeping gene. Scale bar: A, B and E, F, 500 μm.
Fig. 7. Effect of FGF9 treatment on canonical Wnt activation and Dkk1 expression. (A, B) β-galactosidase expression in E12.5 TOPGAL lungs grown in vitro in the absence of FGF9 for 48 h is used to follow the
activation of the canonical Wnt signaling. Note the expression of β-galactosidase throughout the lung epithelium. In the presence of FGF9 (B), there is a clear decrease of β-galactosidase expression in the distal
epithelium but the expression of β-galactosidase in the trachea and primary bronchi is unchanged. (C, D) High magnification of the lungs shown in panels A and B. Note the drastic decrease in β-galactosidase expression
in the distal epithelium upon treatment with FGF9 (D). Whole-mount in situ hybridization for LacZ confirms a significant decrease in LacZ expression, at the mRNA levels, in FGF9-treated lung (compare inserts in
panels A and B). (E, H)Whole-mount in situ hybridization forDkk1 showing up-regulation ofDkk1 expression in the distal epithelium of FGF9-treated lungs (F) compared to control lungs (E). (G, H) High magnification

















Fig. 8. Analysis of gene expression in FGF9-treated lungs. Whole-mount in situ hybridization (WMISH) and semi-quantitative RT-PCR were carried out to investi e and validate changes in gene expression upon FGF9
treatment. (A, B) WMISH for Shh in E12.5 control and FGF9-treated lungs after 48 h of culture shows no significant change in Shh expression throughout the e helium. (C, D) WMISH for Ptc in control and FGF9-
treated lungs after 48 h of culture shows a significant increase in Ptc expression. Ptc is expressed at high level in the mesenchyme adjacent to the distal epithelium. F)WMISH for Ptc in control and FGF9-treated lungs
after 48 h of culture shows a significant increase in Ptc expression. Ptc is expressed at high level in the mesenchyme adjacent to the distal epithelium. (G, H) High m nification of panels E and F. (I–L)Gli-1 expression is
also up-regulated in the distal lung mesenchyme upon FGF9 treatment. (M) Semi-quantitative RT-PCR has been used to investigate changes in gene expression primary culture of lung mesenchyme upon treatment
with FGF9. There is no detectable expression of Dkk1, confirming the absence of epithelial contamination. By contrast, a significant increase in Fgf7, Ptc, and Gl is observed. β-actin has been used as a housekeeping
gene. (N) Determination of the expression of Fgf7, Ptc,Gli-1 and Tbx4 in primary lung mesenchymal cultures treated with SHH. (O)Western blot analysis of the e ession of the cleaved form of GLI3 (also called GLI3-
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significant epithelial contamination in our cultures. As a
comparison, we determined the expression of these genes in
primary lung mesenchymal cultures treated with SHH (Fig.
8N). We observe an increase in Fgf7, Ptc and Gli-1 similar in
intensity to the ones observed after FGF9 treatment.
Interestingly, Tbx4 mRNA levels were decreased by SHH
treatment (Fig. 8N), supporting its known negative regulatory
role on Fgf10 expression. To confirm at the protein level that
FGF9 directly activates the SHH pathway, we examined
specifically the expression of the cleaved form of GLI3 (also
called GLI3-R), which acts as a repressor for the SHH
pathway (Sasaki et al., 1999). Fig. 8O shows a strong
decrease in GLI3-R levels upon FGF9 treatment, thus
validating the results observed at the RNA level (Fig. 8M).
Discussion
FGF9 triggers the proliferation of the lung epithelium via
FGFR2b
Our results confirm the early expression of Fgf9 that Colvin
et al. reported (Colvin et al., 2001). However, we show for the
first time that Fgf9 is expressed at significant levels in the distal
epithelium at E13.5 and E14.5 and that the distal lung
epithelium exhibits a response to exogenous FGF9. In this
study, we mimicked overexpression of FGF9 by adding
recombinant FGF9 to the medium of in vitro cultured E12.5
lungs. The concentration of FGF9 (200 ng/ml) used for this
study is within the lower range of concentration used to test the
effect of FGFs in vitro (250–500 ng/ml for FGF10; 200 ng/ml
for FGF7; Bellusci et al., 1997a; Hyatt et al., 2002) and is
therefore likely to yield important and physiological informa-
tion about FGF9 role in lung development. In addition to the
increase in mesenchymal proliferation and inhibition of
mesenchymal differentiation, we observed a decreased branch-
ing, epithelial dilation and a shortening of the basal–apical axis
of the epithelial cells. Furthermore, we demonstrate that this
effect of FGF9 on the epithelium does not require the
mesenchyme as an intermediate since the isolated epithelium
dilates in response to FGF9 even if it is cultured, devoid of any
adjacent mesenchyme and mesothelium. Conversely, the action
of FGF9 on the mesenchyme does not require the endoderm as
an intermediate since explanted lung mesenchyme, endoderm-
free, expands in the presence of FGF9.
These results raise therefore the possibility that FGF9 plays
an important role on the epithelium during lung development.
Classical inactivation of Fgf9 leads to decreased branching of
the epithelium. The primary cause of this defect has been
attributed to decreased proliferation of the mesenchyme
associated with a severe reduction in Fgf10 expression as the
lung develops (Colvin et al., 2001). Interestingly, at E12.5,
Colvin et al. (2001) report that the branching is affected but the
levels of Fgf10 expression are not drastically reduced, more
particularly in the distal mesenchyme of the main stem bronchi,
leaving therefore open the possibility that, at that stage, the
observed branching defects could also be explained by FGF9acting on the epithelium. Our results indicate that FGF9 is
indeed capable of increasing epithelial proliferation without
decreasing distal differentiation. A similar effect of FGF9 on the
proliferation of the tracheal epithelium has also been reported
(Hyatt et al., 2002). Another finding strengthening FGF9 role
on the epithelium is that Fgf10−/− lungs do exhibit formation of
the first two bronchi. This indicates that FGF10 is not required
for the induction of the first two bronchi in the lung but mostly
needed for the outgrowth of the distal lung epithelium. FGF9
could contribute to the formation of the two primary bronchial
buds, in the absence of Fgf10 expression.
The epithelial receptors responsible for mediating FGF9
activity are still unidentified. FGF9 has previously been
characterized as an activator of the “b” isoform of FGFR3
(Santos-Ocampo et al., 1996). While our work does not exclude
the possibility that FGF9 binds to FGFR3b in the lung
epithelium (Fgfr3b is expressed at high levels in the embryonic
lung, data not shown), it clearly indicates that FGFR2b is needed
for FGF9 to mediate its activity on the epithelium. This is
supported by our results showing that there was no response of
the epithelium of Fgfr2b−/− lungs to FGF9. In the future, it will
be important to investigate whether FGF9 binds directly to
FGFR2b in vivo or if the requirement for FGFR2b is due to the
induction by FGF9 of one or several FGFR2b ligands in the
epithelium. Alternatively, FGF9 could trigger a co-activation of
the FGFR2b signaling pathway independently of FGFR2b
ligands by a mechanism still to be characterized. To determine
whether the non-responsiveness of the epithelium of Fgfr2b−/−
lungs to FGF9 was not due to the fact that these explants are
underdeveloped, we cultured Fgf10−/− lungs that exhibit a
similar phenotype but do express Fgfr2b in the epithelium. In
this case, FGF9 was able to trigger an epithelial proliferation in
Fgf10−/− lungs, supporting our observation that FGF9 acts
directly on the epithelium and involves FGFR2b for its response.
FGF9 acts on the lung mesenchyme to induce proliferation and
decrease differentiation
FGF9 has been reported to affect lung mesenchymal survival
(Colvin et al., 2001). Our results show for the first time that it
also controls mesenchymal proliferation. This proliferation is
likely mediated via the mesenchymal “c” splice forms of
FGFR2 and FGFR3 (Santos-Ocampo et al., 1996). In
accordance with a previous report (Weaver et al., 2003), we
also show that FGF9 has an inhibitory effect on the
differentiation of lung mesenchyme into smooth muscle cells.
In addition, we show here that FGF9 impairs the formation of
endothelial cells and well-structured vascular networks. The
combination of increased mesenchymal proliferation and
decreased formation of two mesenchymal lineages in response
to FGF9 suggests that FGF9 plays a key role in the maintenance
of the balance between proliferation and differentiation of the
mesenchyme. These results strengthen our conclusion that
FGF9 acts directly on the mesenchymal cells to prevent their
differentiation. The molecular mechanisms involved are still
unknown, but results obtained recently in our laboratory
studying the lung phenotype of a mouse model of Apert
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mesenchyme leads also to similar inhibition of differentiation
(De Langhe et al., submitted for publication). These observa-
tions therefore suggest that the specificity of the inhibition of
the differentiation lies in the activation of the classical Ras/
MAPkinase pathway rather than in the isoform of FGFR
receptor being activated in the mesenchyme. We propose that
FGF9 is instrumental to maintain the pluripotency of the
mesenchymal progenitor located in the distal lung mesenchyme
via MAPkinase activation.
FGF9 controls the expression of Fgf10 likely via up-regulation
of Tbx4 and 5
In an attempt to explain the effects of FGF9 in terms of
affected signaling pathways, we analyzed the expression of the
main known signaling molecules. It has been previously
reported that Fgf10 expression is drastically decreased in
Fgf9−/− lungs from E14.5 onwards (Colvin et al., 2001). This
observation suggests that FGF9 is a main regulator of Fgf10
expression during early lung development. Our results indicate
that Fgf10 expression is increased and correlates in localization
to the hypertrophic distal mesenchyme. This may indicate that
there is an increase of relatively undifferentiated cells as FGF10
in the distal mesenchyme has recently been shown to identify
smooth muscle cell progenitors (Mailleux et al., 2005).
Additionally, in response to FGF9, Fgf10 becomes expressed
as a continuum in the distal mesenchyme instead of being
expressed in intermittent domains along the periphery. Howev-
er, the Fgf10 expression domain is never in contact with the
distal epithelium, suggesting that the SHH pathway, shown
previously to negatively regulate Fgf10 expression (Bellusci et
al., 1997b), is functional.
It has been proposed that similar molecular interactions
govern limb and lung development. In the early limb bud,
FGF10 acts to induce Fgf8 expression in the AER (Agarwal et
al., 2003; Galceran et al., 1999). FGF8 then signals back to the
mesenchyme to maintain Tbx5 expression, which in turn
controls Fgf10 expression (Agarwal et al., 2003; Sekine et al.,
1999; Takeuchi et al., 2003; Xu et al., 1998). In the lung, a
similar reciprocal feedback loop may occur. In FGF9-treated
lungs, we find an up-regulation of Fgf10 in the mesenchyme,
and levels of Fgf9 expression are reduced in mice carrying a
hypomorphic Fgf10 allele (Kelly and Bellusci, unpublished
results). Finally, our results show that, just as they are in limbs,
Tbx genes, which regulate Fgf10 expression (Cebra-Thomas et
al., 2003; Sakiyama et al., 2003), appear to be regulated by
FGF9 signaling.
FGF9 represses canonical Wnt signaling in the epithelium
likely via Dkk1 up-regulation in the epithelium
We report a reduction of canonical WNT signaling in the
endoderm, correlating with an increase in expression of Dkk1,
encoding an inhibitor of WNT signaling (Kawano and Kypta,
2003). These data suggest that FGF9 acts on the epithelium to
trigger an inhibition of the canonical Wnt signaling via Dkk1up-regulation. Several observations are supporting this conclu-
sion. First, Fgf9 is significantly detected in the epithelium at
E13.5. Second, from E13.5 onwards, the canonical Wnt
signaling is reduced in the distal epithelium (De Langhe et al.,
2005). Third, the expression of Dkk1 is detected in the
epithelium from E13.5 onwards, coinciding with the onset of
Fgf9 expression in the epithelium. Our results suggest that
FGF9 is a key regulator of Wnt signaling, expressed at the right
time in the distal lung epithelium and acting in an autocrine
fashion to suppress canonical Wnt signaling.
FGF9 triggers the activation of Hedgehog transcriptional
targets in the mesenchyme
Another intriguing and very innovative result is the
relationship between the FGF9 and the hedgehog pathway.
Shh is the only member of the Hedgehog family expressed in
the lung (Bellusci et al., 1997a). Our results indicate an up-
regulation by FGF9 of SHH transcriptional targets Ptc andGli-1
independently of SHH. Our results suggest that FGF9 and SHH
intracellular signaling pathway have common effectors, like
GLI3. Interestingly, FGF9 is not capable of increasing the
expression of all the SHH targets in the lung as Fgf7 expression
(Lebeche et al., 1999) is not up-regulated (data not shown).
However, on isolated mesenchyme, the activation of all the
SHH targets, including Fgf7, is observed. The reason for this
difference might be due to the absence of epithelial/mesenchy-
mal crosstalk that normally occurs during lung development.
The identification of the effectors of the FGF9 pathway in the
mesenchyme and the epithelium will be critical to our
understanding of the complex role of this growth factor during
lung organogenesis.
In conclusion, we have shown for the first time that, in the
lung, FGF9 acts not only on the mesenchyme, but also on the
epithelium. It increases mesenchymal proliferation, decreases
its differentiation and activates transcription of Hedgehog
transcriptional targets. In addition, it acts on the epithelium
via FGFR2b to control its proliferation but not its differentiation
and contributes to the regulation of canonical Wnt signaling in
the epithelium likely via Dkk1 up-regulation.
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